EUVIMEDEUVIMED entdecken
Crossref

ROTAVAC 5D® Vaccine: Recommendations of the Tanzania Immunization Technical Advisory Group

Fausta S. Michael, Florence S. Kabalamu, Mariam M Mirambo, Semvua Kilonzo, Gerald Misinzo, Omary Minzi, Nyanda E. Ntinginya, Mary Mwanyika-Sando, Daniel Ndiyo, Richard Kasonogo, Andrew Bahati, Farida Hassan und 14 weitere

Tanzania Journal of Health Research · 03.03.2026 · 27 (1) · 3237-45

DOI: 10.4314/thrb.v27i1.18 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tanzania Journal of Health Research, online erschienen am 03.03.2026. Verfasst von Fausta S. Michael und 25 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rotavirus gastroenteritis causes most diarrheal deaths, with 95% of cases occurring in low-income countries. The implementation of Rotarix™ vaccine in 2013 in Tanzania, resulted in a significant decrease of Rotavirus positivity and hospitalization among children under 5 years of age. Due to a decrease in the supply of Rotarix™, it was necessary to switch to ROTAVAC 5D® vaccine to ensure a sustained vaccination supply and avoid associated morbidity and mortality as result of the shortage.

Methods

The Tanzania Immunization Technical Advisory Group (TITAG) held its 5th meeting from 21st to 25th February 2022 in Dodoma, during which it reviewed the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to assess the potential switch from RotarixTM to ROTAVAC 5D®.

Results

ROTAVAC 5D® was found to be safe and efficacious with similar margins to other WHO prequalified Rotavirus vaccines including Rotarix™. Although ROTAVAC 5D® is based on human G9P [11] Rotavirus 116E strain, the vaccine offers heterotypic (cross) protection against multiple Rotavirus strains. Taking into consideration of other factors, the costs benefit analysis for the Rotavirus Vaccines (Rotarix™ and ROTAVAC 5D®) proved to be cost-effective relative to no vaccination. The total incremental economic costs per child for Rotarix™ was found to be the least costly and cost-effective compared to ROTAVAC 5D®, but the differences were small and subject to change with minor adjustments to uncertain input variables. Conclusions and Recommendations: The high-quality evidence available has clearly demonstrated that ROTAVAC 5D® (liquid, 5 doses vial) was comparable to ROTARIX™ in terms of safety, efficacy, cross-protection to wild Rotavirus, and cost-effectiveness. Hence, the TITAG recommended the use of ROTAVAC 5D® a five-dose vial (liquid) in Tanzania. Continuous surveillance is crucial for obtaining data on vaccine effectiveness, Adverse Events Following Immunization (AEFIs) including intussusception rates, as recommended by WHO, to make timely decisions regarding ROTAVAC 5D® vaccine use.

Zitieren

APA

Michael, F. S., Kabalamu, F. S., Mirambo, M. M., Kilonzo, S., Misinzo, G., Minzi, O., Ntinginya, N. E., Mwanyika-Sando, M., Ndiyo, D., Kasonogo, R., Bahati, A., Hassan, F., Kaale, E., Chai, J. J., Mahmoud, S., Ali, A. S., Bugoye, F. C., Joachim, G., Mujuni, D., …, & Mshana, S. E. (2026). ROTAVAC 5D® Vaccine: Recommendations of the Tanzania Immunization Technical Advisory Group. Tanzania Journal of Health Research, 27(1), 3237-45. https://doi.org/10.4314/thrb.v27i1.18

Vancouver

Michael FS, Kabalamu FS, Mirambo MM, Kilonzo S, Misinzo G, Minzi O, et al. ROTAVAC 5D® Vaccine: Recommendations of the Tanzania Immunization Technical Advisory Group. Tanzania Journal of Health Research. 2026;27(1):3237-45. doi:10.4314/thrb.v27i1.18

BibTeX
@article{Michael2026,
  author = {Michael, Fausta S. and Kabalamu, Florence S. and Mirambo, Mariam M and Kilonzo, Semvua and Misinzo, Gerald and Minzi, Omary and Ntinginya, Nyanda E. and Mwanyika-Sando, Mary and Ndiyo, Daniel and Kasonogo, Richard and Bahati, Andrew and Hassan, Farida and Kaale, Eliangiringa and Chai, John J. and Mahmoud, Salma and Ali, Ali Salim and Bugoye, Fidelis C. and Joachim, Georgina and Mujuni, Delphinus and Mdachi, Joseph and Nyamungumi, Zainabu and Mkhoi, Mkhoi L. and Bukagile, Abella and Morona, Domenica and Kyesi, Furaha and Mshana, Stephen Eliatosha},
  title = {ROTAVAC 5D® Vaccine: Recommendations of the Tanzania Immunization Technical Advisory Group},
  journal = {Tanzania Journal of Health Research},
  year = {2026},
  volume = {27},
  number = {1},
  pages = {3237--45},
  doi = {10.4314/thrb.v27i1.18}
}
Kostenlos starten →